Imperial College London - Articles and news items

New drug reduces daily menopausal hot flushes by 73%

Industry news / 6 April 2017 / Niamh Marriott, Junior Editor

In a trial carried out at Imperial College, researchers showed that women who suffered seven or more hot flushes a day could reduce the number by 73%…

Mucosis’ needle-free nasal spray vaccine for RSV trial starts

Industry news / 8 November 2016 / Niamh Louise Marriott, Digital Content Producer

Mucosis has begun a first-in-human study of its intranasal Respiratory Syncytial Virus (RSV) vaccine candidate, SynGEM, at Imperial College London…

Scientists find new streptococcus variant causing severe infections

Industry news / 15 July 2015 / Victoria White

Scientists have discovered a new subtype of emm89 streptococcus that has contributed to a rise in disease cases in the UK over the last 17 years…

Gene therapy offers hope for cystic fibrosis patients

Industry news / 3 July 2015 / Victoria White

A therapy that replaces the faulty gene responsible for cystic fibrosis in patients’ lungs has produced encouraging results in a major UK trial…

The role of proteomics in the development of personalised cancer medicine

The role of proteomics in the development of personalised cancer medicine

Issue 2 2013, Proteomics / 18 April 2013 / Pedro R. Cutillas, MRC Clinical Sciences Centre, Imperial College London

Not all cancer patients, even those with the same tumour type, respond to therapy equally well. An understanding of this heterogeneity at the molecular level is crucial for further advances in the development of cancer therapies. Discerning the mechanisms of cancer heterogeneity will lead to a better selection of the most appropriate therapy for each patient and to an improvement in therapeutic outcomes. The success of such personalised cancer therapies requires biomarkers that can be used to stratify patients based on the likelihood that they may respond a particular drug or therapy1. This article discusses the rationale of using proteomics approaches to characterise such biomarkers.

Figure 1: Classification Scheme of GPCRs. R (Rhodopsin-like), S (Secretin-like), G (Glutamate-like), Others (Adhesion, Frizzled, Taste type-2, unclassified)

G protein coupled receptors – exploiting flexible conformations

Drug Targets, Issue 4 2012 / 3 September 2012 / Kathryn L. Chapman, Imperial Drug Discovery Centre, Imperial College London and John B.C. Findlay & Gemma K. Kinsella, Department of Biology, National University of Ireland Maynooth

G-protein coupled receptors (GPCRs) are a diverse super-family of proteins located within the plasma membrane of eukaryotic cells which have a common architecture consisting of seven-transmembrane (7-TM) segments, connected by extracellular (ECL) and intracellular (ICL) loops. They differ from other 7-TM proteins in their ability to activate guanine-nucleotide binding proteins or β-arrestin and so initiate a signalling cascade. They have a wide range of physiological roles and provide many successful drug targets, playing a role in disorders including allergies, cardiovascular dysfunction, depression, obesity, cancer, pain, diabetes and a variety of central nervous system conditions. This review will give a general overview of GPCRs and how their structures and activities can be used in drug discovery…

The current challenge

Issue 3 2005, Past issues / 22 August 2005 / Professor Naomi E. Chayen, Biological Structure and Function Section, Division of Biomedical Sciences, Imperial College London

We are currently living in an exciting age, where for the fist time ever, human diseases are being understood at a molecular level. Protein crystallography plays a major role in this understanding because proteins, being the major machinery of living things, are often the targets for drugs.


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...